



Financial Tear Sheet

CORPORATE PROFILE

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

PRIMARY IR CONTACT

RussoPartners/LLC

Alex Fudukidis

Phone: (646) 942-5632

E-mail:


alex.fudukidis@russopartnersllc.com

STOCK PERFORMANCE

ONS (Share)

Exchange	NASDAQ (US Dollar)
Price	\$0.89
Change (%)	0.00 (0.00%)
Volume	1,936
Today's Open	\$0.88
Previous Close	\$0.89
Intraday High	\$0.89
Intraday Low	\$0.88
52 Week High	\$2.30
52 Week Low	\$0.78

Data as of 04/19/18 3:46 p.m. ET



LATEST NEWS

April 17, 2018

Oncobiologics Appoints Randy Thurman To Board Of Directors

March 27, 2018

Oncobiologics Appoints Dr. Joerg Windisch To Board Of Directors

February 14, 2018

Oncobiologics Reports First Quarter Fiscal Year 2018 Results

UPCOMING EVENTS

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
04/17/18	3
04/17/18	4
04/17/18	3
04/17/18	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.